Replies to post #109359 on Regen BioPharma Inc (RGBP)

[29YEARINVESTOR]

It’s easy to find current active Dyo bio sites with a simple search!
RGBP’s active new Dyo-Bio Dream Team:
Active current sites!

https://www.datanyze.com/companies/dyo-bio-technologies/473660573

Dyo-bio Operating Status active
https://www.crunchbase.com/organization/dyo-biotechnologies
Revenue
$5 M
Employees
26

https://www.linkedin.com/in/harry-lander-5a82b610b

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168267352

[29YEARINVESTOR]

Submitted 15 Mar 2022 Preclinical trials in Myelodysplastic syndromes in USA (IV) (Regen Biopharma pipeline)
10 Mar 2022 Preclinical development in Breast cancer and Myelodysplastic syndrome is ongoing USA

https://adisinsight.springer.com/drugs/800037634

FDA can go back and forth before fast track acceptance.
https://www.prnewswire.com/news-releases/regen-biopharma-inc-announces-program-to-fast-track-its-checkpoint-inhibitor-program-utilizing-modified-mrna-and-sirna-technologies-301499817.html

[Mutat]

You said “ another scam company called Regen run by a guy who has never actually accomplished anything”

1). 4/8/21 Dr Koos files an 8K which in and of itself is a dead give-a-away of what he’s up to. The question begs why would he file an 8K that specifically gives himself exclusive control of voting rights in negotiations for the sale of the company during the bidding process that’s specifically intended to prevent a Hostile Take Over? And in doing this he states quote: “persons of interest who want to ACQUIRE RGBP must negotiate directly.” This is in reference to himself having sole control of voting rights that this 8K gives him. Other words, negotiations for sale of the company can’t go around him to his board which is a typical move in any hostile take over. This by itself reveals what he’s up to in addition to MANY other factors shown below. https://sec.report/Document/0001607062-21-000145/ ;
2). Dr Koos recently hired a Firm to get OTC current with FULL disclosure reporting. This has to do not only with SEC compliance to remain listed on the OTC beyond September 2021 but ALSO it provides transparency for any potential Big Pharma buyers that would never consider buying a company otherwise. 
3). on 6/1/21 Dr Koos files another 8K that has to do with resolving a lawsuit. This would be important to any potential buyers for reason a pending unresolved lawsuit would likely complicate negotiations of a buy out, or it would be a deterrent altogether. https://sec.report/Document/0001607062-21-000145/ ;
4). we see him moving to get all his expired Patents updated. Logically this move would be consistent with preparing for an acquiring company to take over the patents then turn around and file an FDA IND post buy out in order to immediately place those candidate drug Patents in their clinical trials pipeline. 
5). lastly he’s not updating the company website that’s been outdated for years. Why would he invested time, energy, and money in updating his company website if he’s about to sell the company? 
On April 7, 2021 KCL Therapeutics, Inc. (“KCL”) (RGBP subsidiary) entered into an agreement with Oncology Pharma, Inc. whereby KCL granted to Licensee an exclusive right and license for the development and commercialization of certain intellectual property for the treatment in humans of colon cancer for a term of fifteen years from April 7, 2021. 
As consideration to KCL for the rights and license granted pursuant to the Agreement Licensee shall: pay to KCL a nonrefundable fee of Fifty Thousand common shares of Oncology Pharma, Inc. no later than April 20,2021, pay to KCL royalties equal to five percent (5%) of the Net Sales as Net Sales are defined in the Agreement of any Licensed Products in a quarter. pay to KCL ten percent (10%) of all consideration (in the case of in-kind consideration, at fair market value as monetary consideration) received by Licensee from sublicensees, excluding royalties from sublicensees based on Net Sales of any Licensed Products for which KCL receives payment. ONCP is trading at $33 at an $847 million market valuation, the 50,000 shares are worth $1,500,000) 

$RGBP $RGBPP THIS NOW HAS BUYOUT WRITTEN ALL OVER IT. WHERE IN THE OTC ARE YOU GOING TO FIND A CEO THAT HAS PUT OUT 16 8K'S IN 4 MONTHS AND HASN'T SAID A WORD. TOTAL SILENCE NO ATTEMPT TO BLOW SMOKE OR PUMP STOCK.


RGBP filed an 8k reporting that on July 8 BF Borgers CPA PC; Regen Biopharma Inc.’s independent registered public accounting firm, began the audit of financial statements for the fiscal year ended September 30, 2020 required to be included in Regen’s Annual Report for the fiscal year ended September 30, 2020 to be filed with the United States Securities and Exchange Commission on Form 10-K. Regen’s financial statements for the fiscal years ended September 30, 2019 and September 30, 2018 (included in the Company’s Annual report for the fiscal year ended September 30, 2019 filed on Form 10-K) had also been audited by Borgers. The commencement of this audit of the Company’s financial statements is a further step taken by the Company towards curing the Company’s delinquency with regard to periodic reports required to be filed with the United States Securities and Exchange Commission. 

On July 13 RGBP filed an 8k listing the Company’s issued patents and pending patents:
1. GENE SILENCING OF THE BROTHER OF THE REGULATOR OF IMPRINTED SITES (BORIS): Patent No: 8263571
2. METHODS AND MEANS OF GENERATING IL-17 ASSOCIATED ANTITUMOR EFFECTOR CELLS BY INHIBITION OF NR2F6 INHIBITION: PatentNo :11,053,503 
3. METHODS OF SCREENING COMPOUNDS THAT CAN MODULATE NR2F6 BY DISPLACEMENT OF A REFERENCE LIGAND: Patent No: 10,088,485
4. MODULATION OF NR2F6 AND METHODS AND USES THEREOF: Patent No: 9091696
IP for which a Notice of Allowance has been granted. A Notice of Allowance is notification by the USPTO to the applicant that the USPTO intends to issue a patent 
5. ANTIGEN SPECIFIC MRNA CELLULAR CANCER VACCINES: Application Number: 15/162,370
IP for which Patent Protection has expired due to non payment of fees for which revival is in process: 
6. METHOD OF CANCER TREATMENT USING SIRNA SILENCING Patent No: 8389708
IP for which a Notice of Allowance was granted but classified as abandoned by the USPTO. Revival in progress. 
7. UNIVERSAL DONOR CHECKPOINT INHIBITOR SILENCED/GENE EDITED CORD BLOOD KILLER CELLS: Application Number: 15/494,358
Active Patent Applications: 
8. ENHANCED DENDRITIC CELL IMMUNE ACTIVATION BY COMBINED INHIBITION OF NR2F6 WITH CANNIBIDIOL; Application Number 17035955.
9. REDUCTION OF POST-SURGERY CANCER METASTASIS BY COMBINATION OF CANNABIDIOL AND NR2F6 INHIBITION. Application Number 17037284
10. SUPPRESSION OF PATHOLOGICAL ANGIOGENESIS BY INHIBITION OF NR2F6 Application Number 17087386
11. STIMULATION OF T REGULATORY CELLS BY CANNABIDIOL AS A MEANS OF TREATING ARTHRITIS AND AUTOIMMUNITY Application Number 17010720
12. SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN HUMANS Application Number 15820324
13. SMALL MOLECULE MODULATORS OF NR2F6 ACTIVITY. Application Number 15364111
Patent issued to Zander Therapeutics, Inc. derived from intellectual property licensed by Zander Therapeutics Inc. from KCL. 
14. CANINE AUTOLOGOUS IMMUNOTHERAPY USING DENDRITIC CELL INDUCED CANCER.